# About Melanotan II Reviews — Independent Editorial Publisher > About Melanotan II Reviews: an independent editorial project that summarizes peer-reviewed research on Melanotan II. Not a clinic, not a vendor, not affiliated with any supplier. who we are, what we are not, and how this works. ## What This Site Is Melanotan II Reviews exists because the information environment around MT-II is dominated by two registers that both fail the reader in different ways: the aspirational marketing register (TikTok, supplement forums, bodybuilding communities) that presents the compound in uniformly positive terms and virtually never mentions the case reports [20]; and the reflexive cautionary register that treats the compound as too dangerous to discuss at all. The research record supports neither. MT-II was synthesized and studied by serious pharmacologists at a legitimate research institution — the University of Arizona's Departments of Biochemistry and Pharmacology — under formal investigational drug research protocols [1]. Two of the three controlled human clinical trials produced statistically significant results at their stated endpoints [2][3]. The compound's mechanistic research has contributed to our understanding of melanocortin receptor pharmacology in ways that the FDA-approved derivative bremelanotide's clinical story documents [17]. This is a research record worth reading accurately. The record also contains serious adverse event documentation — rhabdomyolysis, ischemic priapism resulting in permanent erectile dysfunction, renal infarction, melanoma association, and eruptive dysplastic nevi [9][10][11][12][13][18] — that the marketing register systematically omits. Both sides of the record deserve accurate representation. This site attempts to provide that representation. It is an editorial commentary on publicly available research. It is not a source of dosing guidance, medical advice, clinical recommendation, or purchasing information. ## Editorial Standards Every quantitative claim on this site is sourced to a specific published study. Every citation is linked to its PubMed, PMC, or publisher page. Where the evidence base is thin — as it is for many MT-II endpoints — we say so explicitly. Where the literature contains uncertainty or contradiction, we document that rather than resolving it artificially. The University of Arizona research lineage for MT-II runs from the early 1990s synthesis work through the phase I tanning pilot (Dorr et al. 1996) [1], through the erectile dysfunction crossover trials (Wessells et al. 1998 and 2000) [2][3], and into the derived compound's FDA approval in 2019 [17]. The case-report literature spans 2012 through 2026 [9][10][11][12][13][14][18]. The qualitative social science literature documenting user experience patterns is more recent (2021–2025) [16][19][20][21]. We draw on all three bodies of literature. We do not invent findings. We do not interpolate between studies to suggest outcomes not actually documented. We do not use language that recommends use or discourages use — we describe what was studied, in what species, at what doses, with what outcomes. The reader determines what to make of the record. This site does not feature a named author, a featured clinician, or an editorial team with individual credits. It is an anonymous editorial project. The name 'Melanotan II Reviews' is an editorial framing of our position relative to the literature — a publication that reviews the research record — not a claim about our clinical credentials or services. We have no clinical credentials. We offer no clinical services. ## What We Are Not We are not a clinic. The word 'reviews' in our name describes our editorial function — reviewing and summarizing research — not a professional clinical review service. We do not have doctors, pharmacists, or other healthcare professionals on staff. We do not provide consultations, prescriptions, or treatment recommendations. We do not sell MT-II or any other compound. We are not affiliated with any vendor, manufacturer, distributor, or supplier of MT-II or related compounds. We have no commercial relationship with any supplier and receive no compensation for any commercial outcome. We do not provide medical advice. Nothing on this site should be interpreted as a recommendation to use, purchase, or avoid any substance. The information here is editorial commentary on published research. Individuals with questions about any health concern should consult a qualified healthcare professional. Melanotan II is not approved for any human indication in any jurisdiction. This site does not suggest otherwise. The research summarized here was conducted under formal investigational drug research authorization; the clinical trials documented here were not consumer-directed endorsements. The compound's regulatory status — unapproved, and prohibited by WADA for athletes — is documented on this site clearly. This is an independent editorial research digest, not a vendor, not a clinic. --- An independent editorial reading of the peer-reviewed record — not a clinic, not a vendor, not a dosing guide.